EMA Authorised: Lyumjev (previously Liumjev) (insulin lispro) — Eli Lilly Nederland B.V.

View source ↗

Summary

Lyumjev (insulin lispro) has been authorised in the EU for diabetes mellitus, with Eli Lilly Nederland B.V. as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Lyumjev (insulin lispro)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Eli Lilly Nederland B.V.. Decision date: 09/07/2026